ABN’s scientists are leaders in the development of solutions for protecting, stabilizing and delivering sensitive bioactives including live probiotics and biologics in human nutrition and health, as well as agricultural and industrial applications. The human applications have been modeled in animal studies. The following are papers published by these scientists regarding these technologies:
- Vaccine 29 (2011) 2336-2340. Oral vaccination of Atlantic salmon (Salmo salar) against salmonid rickettsial septicaemia.
- Fish and Shellfish Immunology 54 (2016) 54-59. Protective oral vaccination against infectious salmon anaemia virus in Salmo salar.
- A novel preservation and delivery technology for live probiotics, enzymes and vitamins.
* NOTE that ABN has recently sold and/or exclusively licensed to a third party the technology for use in the field of animal health and nutrition; as a result, ABN no longer engages in that business and the technology cannot be used in the animal field.